Avacta Group PLC Cash Flow Conversion Efficiency
Avacta Group PLC cash flow conversion efficiency. Based on the latest financial reports, Avacta Group PLC (AVCT) has a cash flow conversion efficiency ratio of -93.806x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-13.51 Million ≈ $-1.64K USD) by net assets (GBX144.00K ≈ $17.52 USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Avacta Group PLC (2001–2024)
Cash flow conversion efficiency of Avacta Group PLC from 2001 to 2024. This chart illustrates how Avacta Group PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. View AVCT live share price for real-time trading data and today's change.
Avacta Group PLC Cash Flow Conversion Ratio Explained
Avacta Group PLC cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Avacta Group PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Avacta Group PLC ranked by their cash flow conversion efficiency. Also see Avacta Group PLC market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Saferoads Holdings Ltd
AU:SRH
|
-0.038x |
|
Metalex Ventures Ltd.
V:MTX
|
-0.095x |
|
amalphi ag
F:AMI
|
N/A |
|
Dharani Sugars&Chemicals Limited
NSE:DHARSUGAR
|
-0.229x |
|
Fuller Smith & Turner
LSE:FSTA
|
0.093x |
|
Quest PharmaTech Inc
V:QPT
|
-0.002x |
|
Professional Diversity Network Inc
NASDAQ:IPDN
|
-27.134x |
|
QcX Gold Corp
V:QCX
|
-0.031x |
Annual Cash Flow Conversion Efficiency for Avacta Group PLC (2001–2024)
The table below shows the annual cash flow conversion efficiency of Avacta Group PLC from 2001 to 2024. Review AVCT free cash flow debt coverage to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | GBX9.28 Million ≈ $1.13K |
GBX-23.60 Million ≈ $-2.87K |
-2.543x | -272.78% |
| 2023-12-31 | GBX21.80 Million ≈ $2.65K |
GBX-14.87 Million ≈ $-1.81K |
-0.682x | +23.47% |
| 2022-12-31 | GBX18.44 Million ≈ $2.24K |
GBX-16.43 Million ≈ $-2.00K |
-0.891x | -79.15% |
| 2021-12-31 | GBX41.22 Million ≈ $5.02K |
GBX-20.51 Million ≈ $-2.49K |
-0.497x | -189.48% |
| 2020-12-31 | GBX61.93 Million ≈ $7.53K |
GBX-10.64 Million ≈ $-1.29K |
-0.172x | +32.71% |
| 2018-07-31 | GBX21.41 Million ≈ $2.61K |
GBX-5.47 Million ≈ $-665.30 |
-0.255x | -79.97% |
| 2017-07-31 | GBX29.89 Million ≈ $3.64K |
GBX-4.24 Million ≈ $-516.01 |
-0.142x | -20.19% |
| 2016-07-31 | GBX35.86 Million ≈ $4.36K |
GBX-4.23 Million ≈ $-515.03 |
-0.118x | +10.19% |
| 2015-07-31 | GBX19.13 Million ≈ $2.33K |
GBX-2.52 Million ≈ $-306.00 |
-0.131x | -352.36% |
| 2014-07-31 | GBX28.84 Million ≈ $3.51K |
GBX-838.00K ≈ $-101.96 |
-0.029x | +67.18% |
| 2013-07-31 | GBX15.55 Million ≈ $1.89K |
GBX-1.38 Million ≈ $-167.54 |
-0.089x | -111.16% |
| 2012-07-31 | GBX16.96 Million ≈ $2.06K |
GBX-711.00K ≈ $-86.51 |
-0.042x | +19.54% |
| 2011-07-31 | GBX11.44 Million ≈ $1.39K |
GBX-596.00K ≈ $-72.52 |
-0.052x | +70.16% |
| 2010-07-31 | GBX9.97 Million ≈ $1.21K |
GBX-1.74 Million ≈ $-211.83 |
-0.175x | +48.24% |
| 2009-07-31 | GBX8.30 Million ≈ $1.01K |
GBX-2.80 Million ≈ $-340.56 |
-0.337x | -26.84% |
| 2008-07-31 | GBX4.87 Million ≈ $592.42 |
GBX-1.29 Million ≈ $-157.56 |
-0.266x | +44.06% |
| 2007-07-31 | GBX2.63 Million ≈ $319.87 |
GBX-1.25 Million ≈ $-152.09 |
-0.475x | +95.21% |
| 2006-04-30 | GBX14.00K ≈ $1.70 |
GBX-139.00K ≈ $-16.91 |
-9.929x | -148.21% |
| 2005-04-30 | GBX21.00K ≈ $2.56 |
GBX-84.00K ≈ $-10.22 |
-4.000x | -916.22% |
| 2004-04-30 | GBX1.03 Million ≈ $125.81 |
GBX-407.00K ≈ $-49.52 |
-0.394x | -315.55% |
| 2003-04-30 | GBX-230.00K ≈ $-27.98 |
GBX-42.00K ≈ $-5.11 |
0.183x | -8.87% |
| 2002-04-30 | GBX-529.00K ≈ $-64.36 |
GBX-106.00K ≈ $-12.90 |
0.200x | -47.29% |
| 2001-04-30 | GBX-363.00K ≈ $-44.17 |
GBX-138.00K ≈ $-16.79 |
0.380x | -- |
About Avacta Group PLC
Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. Its lead product candidate is AVA6000, a peptide drug conjugate form of doxorubicin, which is an approved cancer drug with known severe toxicities. The company is developing AVA6103, a peptide drug conjugate technology designed to deliver exatec… Read more